Alcobra Ltd. to Present Results of Phase II Fragile X Trial in a Conference Call & Webcast Presentation on Wednesday, June 24

TEL AVIV, Israel, June 23, 2015 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will host a conference call and simultaneous webcast presentation to present results from the Phase II clinical trial of MDX in adolescents and adults with Fragile X Syndrome on Wednesday, June 24, 2015 at 8:00am Eastern Time.

Alcobra's management will be joined by Dr. Elizabeth Berry Kravis, MD, PhD, Professor of Pediatrics, Neurological Sciences, and Biochemistry at Rush University Medical Center, and the Principal Investigator of the study.

Conference Call & Webcast
Wednesday, June 24 @ 8:00am Eastern Time/5:00am Pacific Time
Domestic: 855-469-0611
International: 484-756-4341
Passcode: 65964631
Replays, available through July 8, 2015
Domestic: 855-859-2056
International: 404-537-3406
Passcode: 65964631

About Alcobra Ltd.

Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and Fragile X Syndrome. For more information please visit the Company's website,, the content of which is not incorporated herein by reference.

CONTACT: U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661

Source:Alcobra Ltd.